# Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy

> **NCT00281255** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Pennsylvania**

## Conditions studied

- Cardiovascular Diseases
- Cardiomyopathy, Dilated
- Heart Diseases
- Heart Failure, Congestive

## Interventions

- **DRUG:** Allopurinol
- **DRUG:** Dobutamine

## Key facts

- **NCT ID:** NCT00281255
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2003-06
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Infeasible
- **Last updated:** 2013-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00281255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00281255, "Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00281255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*